LCM
RXRX icon

LCM Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

LCM Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55K Buy
15,000
+3,000
+25% +$9.99K 0.02% 123
2026
Q1 		$36.8K Hold
12,000
– – 0.02% 107
2025
Q4 		$49.1K Hold
12,000
– – 0.02% 108
2025
Q3 		$58.6K Hold
12,000
– – 0.03% 104
2025
Q2 		$60.7K Hold
12,000
– – 0.03% 103
2025
Q1 		$63.5K Buy
+12,000
New +$87.5K 0.04% 99

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LCM Capital Management's RXRX Position: Q2 2026 in Review

LCM Capital Management increased its Recursion Pharmaceuticals (RXRX) stake by 25% in Q2 2026, buying an estimated $9.99K and bringing the position to 15,000 shares worth $55K. The position accounts for 0.02% of the portfolio, ranked #123.

LCM Capital Management first reported a position in RXRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $63.5K in Q1 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • LCM Capital Management held 15,000 shares of Recursion Pharmaceuticals worth $55K as of Q2 2026.
  • LCM Capital Management bought 3,000 Recursion Pharmaceuticals shares in Q2 2026, an estimated $9.99K.
  • Recursion Pharmaceuticals made up 0.02% of LCM Capital Management's portfolio in Q2 2026, its #123 holding.
  • LCM Capital Management first reported a position in Recursion Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • LCM Capital Management's Recursion Pharmaceuticals position peaked at $63.5K in Q1 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on LCM Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.